Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...

Dr. Raheja has expanded psychiatric care through telepsychiatry, bringing services to rural Wisconsin at Thedacare Regional ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

In the meantime, a general communications gag order bans any CDC scientist from submitting any new scientific findings to the ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

The Company will be focusing on the following programs with Bucillamine: Revive is targeting nerve agent exposure as its initial indication for its medical countermeasures program. Nerve agents are ...

Medically reviewed by Kayla Girgen, RD Persistent sleep struggles, especially due to insomnia, can be a major disruption to ...